XXXX everyone, to and Sam. Thanks, afternoon, Good our earnings third welcome quarter call.
me our each review dynamics Elaine across on business ongoing Officer. our Here our third updates Financial with discuss key will is of market evolving Birkemeyer, provide commercial financial we the Today, Chief our quarter, results for X and initiatives. progress
lymphedema the of cover access support and readiness sales order to to development and platform. these and further launch reminder, in generation initiatives next-generation our our operations, a and technology evidence patient investments workflow-related As clinical of the platform
year-over-year $X.X year guidance airway to update increased $XX.X year-over-year million, strategy.
Total to also increased to X.X% revenue clearance revenue on capital X% year-over-year million. million. the third our We allocation an quarter our provide business, In XXXX XX.X% grew revenue lymphedema full revenue in $XX.X and will and
XXX from year-over-year basis lower the increased improvements was representing delivering of our year-over-year margin consecutive and resulting a of gross result Margin costs improvement EBITDA several in past expansion XX.X% commitment our over improvements grew primarily design points quarter balancing XXth Our leverage.
From expenses, the year-over-year. in QX, cash material reflecting perspective, operating generation the warranty to years.
Adjusted equivalents of operational and XXXX. products cash increased as with of business. by to maturity both cash cash million investments our in million, balance focus sequentially cash of a indicative increasing The and and cash are our in on EBITDA and profitability sequential $XX.X and in XX, our adjusted September growth $X.X balance continued continued
to key pump increased spoke with productivity to our due metrics, to our impact approach third I results expectations On compression across the were to our pneumatic a our factors. Medicare sales documentation quarter QX the below administering pleased call, confluence While on requirements of multiple our main X administrators' performance revenue of LCD. lymphedema due the rep
During our saw quarter, the activities. strong in execution third mitigation we
airway our was for perspective, lymphedema than continue buying In see we products. to growth, strong DME However, continued year-over-year impacted growth to but greater to led slightly originally business, see results.
From clearance the and extent business a expected. clinician fundamentals business uneven we demand patient a in to patterns our
our performances, technology on do Today, simplifying sustaining review and to so ability our lymphedema record We modernization I'll front topics. lymphedema. beginning our respective X growth our strong further discussion line through back-office in of product while confident shareholder our I'm bottom focus of the track let's line and approach innovation.
Driving service patients performance.
With fortifying and sales are remain that a and priorities, concerted voice backdrop, channels, business main with revenue top amplifying value taking providers our the to and and through work
relative for particularly from performance, compression coverage QX update policy our and of regarding the devices. policy on CMS major channel to announcement to an review dynamics pneumatic the changes Medicare a encouraging recent second, First,
As to account a for documentation the the our reminder, discussed the for administrators' compression associated change complete unexpected pneumatic increase for and revised the in of Medicare XXXX or on year QX interpretation we expectations required full the PCDs, XXXX for earnings LCD collection devices, in call, claims.
who sourcing the with the documentation required our this details. collect the added Tactile, on For for clinicians work to responsibility falls prescribing sales reps,
increased vein reminder, the have Medicare productivity our who of gathering centers, payers.
Because our and regardless whole. across a this patients treat on documentation across all type, therapists impacts a oncology As lymphatic reps points call patients, insurance and commercial sales practices, reps' as sales burden vascular government support reps our
denials. activities this claim submission, it disproportionately has while sales across While clear, shipment to all documentation extend collection time for order product impacts line the also patients, channels.
To completion of resulted from and rate claims be Medicare additional a the it to higher impacts in tends claims not
not number audits. post-payment increased of also seen have an Medicare We
of quarter out strong as with by dealing the sequential full generation.
Despite management results patients, this for a flat impact documentation mitigate X.X% the to seen remained exactly grew in have this channels our across our dynamics how evidenced gained roughly were year-over-year now much quarter of experience a working these policy in insight are collection changes greater on we've and Our revenue interpretation, LCD With turbulence. our and full into basis. sales in increased Medicare the requirement cash strategies playing lymphedema sequential cycle
customer-facing modernized and we've workflow-related internal-facing Specifically, tools. expanded and
with strong the to adoption received We've we through these a tool, method patient are seeing more of prescriber piloted help on For launch. and and have national previously days experience to insurance verifying early example, feedback the of e-prescribing collection. positive tool launched data our migrated efficient we streamline required electronic e-prescribing nationally
tool equipped with to to possible.
From XXXX. administrative burden efficient internal best processes we which strategy process Importantly, streamlined enhance order back-office of they we deploy leverage as our in to and documentation directly update our operations. to to our we've be prioritize new indicative to to patient early we reps.
Further and our resources on policies, business CRM, and their efficiency, sales of of to in select efficiency human and fully respect reps will an better continue this mitigating to work the further the portions providers reps With drive coverage internal plan new gathering current timely redeployed the speed our technologies and patients in work also we support redesigned various remain and so capital, implementation sales as have organize sales people with tools QX, can and accelerated from to engagement. perspective, tools These our
documentation We also added incremental contractor with resourcing to assist efforts.
of are performed make to demos with education as that our consultants, patient the known percentage in-home Finally, patient increasing progress PECs. continue by we also
QX of This XXXX. and our from in-home the performed end versus of XX% up PECs by quarter, XX% in XX% at demos were
end We in-home are least the continued demos at by complete XX% and XXXX. this pleased continue with expect growth of to staff to PEC of our
quarter the Regarding up second for and we the ended from quarter the reps, sales target headcount, full the within with year. range end third XXX our of XXX at
year-over-year in third policy ability as as month, the be to in in for demonstrated aforementioned our channel win also sales patients the both commercial our upcoming lymphedema for productivity, in quarter, an effect. digits will reflecting our confident underlying Coverage the XXXX, grew Our fundamentals on and commercial Despite mix With that solid leave Medicare sole and using the in of was VA a be rep strong standard-of-care.
Collectively, a performance, quarter and XXXX. growth clinical with business. to the for Determination, into channels. Both impact will encouraging coverage in and double strong sales publication aided build trial PCDs.
Last or capital LCD story on tools want the particularly us retired announced third We view the versus overall this the products veterans pivot current change of combined demand XX%.
Strength context positive positive our year-over-year by in lymphedema CMS for I channel policy enhancements, Flexitouch XX, underlying and instead VA QX over positive the through existing a by was investments XX% the and momentum for results Flexitouch coverage growth process National with impressive exclusively and recent with human NCD, to November these up that policy that driven quarter.
even to pump we've internal meet the a if some in began PCDs.
Since similar adjudicating and NCD adapt advanced but for particularly which, established patient. advanced sets processes was for adjudication LCD policy try example, the XXXX, with a that requirements, to areas did basic followed documentation define policies LCD The before the specific to pump an PCDs basic advanced established under reimbursement claims and eligibility basic the and LCD, receiving pump, coverage on patient context, a the our clinical Tactile As LCD and related terms own stringent of creation until policy requires needs and eligibility based refine brief XXXX of of requirements requirements the claims coexisted for patterns. have policy, in NCD some conflict, our continued evolving approach their the the also the more MACs of and not adjusted when LCD, MACs Flexitouch. for versus of the Tactile the
policy initiating adjudicate this is can a greater clinically for needs, With case-by-case therapy the NCD. disruption. changes the the and retirement of only But supported. flexibility in of claims for patients.
Coverage create case we if consider on this LCD forward to moving short, positive including Flexitouch MACs in for will for This the In mid-November, optimistic. provides based the are change, patient Tactile PCD
history, knowledge policy of submitting over adjudication is a of claims the including NCD, have experience in and decade where audits language. under We extensive there the NCD ambiguity
claims mobilize partners monitoring for adapt processing while we needed, and the quickly and implement education can rates. tool, our and sales force training adjustments, success e-prescribing clinician As
and associated NCD ] the clinically interpretation the LCD monitoring policy appropriate.
In continue in change the similar own NCD to interpretation stated have patients will patient be their the coverage to current policy for advocating the which of their terms. access, the they medium as some near Ultimately, we and If with lymphedema turbulence the expect the be earlier, behavior language to [ believe summary, we we'll ambiguity. MACs and LCD for As therapy be may diminish to good position. adjudication recent choose, apply policy, NCD does can
channel QX impacted directly the sales commercial With we to believe channel the improve Medicare indirectly negatively QX sole sales and forward. in will moving a dynamics and change policy, that NCD
of access LCD and retirement MACs policies will conflicting their make total of life-changing pleased to treatment Medicare with to was patient-friendly patients that change elimination a believe gain the represent for the the are for unexpected, lymphedema. the options decision easier we While it
leader, space, initiatives and this advocacy step policy professional and which the help changes. and proud closely have As in pushed this of of leader feel way the with to societies work societal responsibility industry the I'm is change. market MACs, our has lead for team entire years policy CMS we this coalitions, every worked We the for done as the our to influence have
a review Turning on of basis, but now a dynamics. seasonal airway of clearance. expected to up AffloVest Sales due to year-over-year down sequentially as were
strictly seasonal increase is it allergies, While the influenced and illnesses not prevalent respiratory bronchiectasis November seasonal, itself which by like most the in are and May. associated flu, is changes in through cold
our patients uneven also of and a that large seasonal performance that of undertreated. bronchiectasis there buying remain patterns dynamics, handful these Beyond We customers. across undiagnosed is our by affected a encouraged are DME was number
in organizations in AffloVest and their providers bronchiectasis and and training sales clearance airway Our sales partners role our experts care. the DME in educating the of are
is AffloVest for We patients. compelling, continue that believe differentiated to a these offering
within said, both that cash and mentioned in with million million. and demonstrate our Medicare $XXX bright in respect have effect VA several commercial cumulative XXXX.
We continued of challenges channel to revise $XXX guidance range As our we business quarter, and to in us expect the operationally the now the airway spots total leverage, momentum QX's the led generation revenue That of growth clearance earlier, profitability, further for channels. and had revenue financially to
EBITDA And million. to and side, are that as $XX guidance result, On year-over-year of as our continued we we to strength EBITDA adjusted a in million to continue. new for the expect $XX range mentioned, raising a increases profitability adjusted to deliver
quarter to lowest any several ability lymphedema our strongest reasons during being the patient the optimistic be our at have year. perspective. to year for is strong from co-pays We the a due to point close out in at business revenue the QX typically
of As initiatives. mode execution shared, our in still current we strong commercial are
clinicians and Nimbl and e-prescribing and and back-office are patients. of improvements, value support among technology versus enthusiasm investing We increasing of activities.
We the non-selling workflow-related standard-of-care perform and launch published clinical is generating including deploying strong administrative rollout results, support and PAC which our of national to Flexitouch the
As addition of and our our of leading is clinically-proven many the of you therapy are to aware, important solutions. next patient-focused lymphedema PCD portfolio Nimbl generation an basic
by to the survivors. of first cancer treatment, phase patient is extremity a upper Nimbl's targeted specifically The introduction market dominated breast group for
breast are disease ordeal fact, and they of often cancer affected unprepared with through now the learn In to surprised lymphedema, they up been to lifelong XX% are no breast going a have and of progressive diagnosed treatment, with that chronic cancer survivors by cure. new after
and trunk, seek option Nimbl's For hosing while still and XX% and design these the and best perspective, its kind, swelling travel. home that ideal providing device. or physical burden breast, our a and Nimbl.
From daily limits It convenient the at constant go. on time-consuming more now a mobility, of the discomfort the XX% have is reduces treat, the and They making use of difficult of therapy the generation patients, physiological hands is to that activity treatment, it arms patients therapy for PCD possible. smallest less feature uses XX% is Nimbl compact previous design lighter, and smaller than and an with
and both improve designed to treatment to digital to compelling application, and simple to their patients to aiding been Kylee its addition change providing to symptoms more these with the track as results positive Nimbl our increased groups care and and design also in usage role their this patient-centric features, feedback from share Kylee offers free in appreciate option increase In team.
Early connectivity way a patients and clinical engagement. value adherence specifically therapy outcomes.
Patients connectivity clinicians has
are lymphedema about expanding published This was of of in the perspective, in results first new that in clinical of with of events, in group, the pathway. positive value most lower the patients extremity patients. investigating among excited Nimbl publication presenting lymphedema lower girth, of clinical the lymphedema assess conditions the trial XX% their patients we course extremity include of secondary increases skin was the This with results high common in largest and a trial clinical X over VA the announced half We platform, be we'll to shows study PCDs lymphedema the the as Flexitouch care hyperpigmentation, this primary year. treatment the XXXX.
From evidence use study of demonstrated stage the prospective among clinical important and U.S., and mild and Flexitouch for ever including and efficacy the and disease limb reductions scores, improvements significant endpoints, quality in in is therapy.
Further, across it cellulitis of compliance earlier life September,
pleased and appropriate speed process, study for million today to X to patients sharing patient lymphedema Our access focus data ongoing for in date group, this our strong of therapies access solutions to soon have foundational to to the forward peer-reviewed to track future access advocacy improving of more meantime, Tactile's an initial to are served as strategy will look able.
Delivering and the this even in we're area innovative look Flexitouch sales become to care.
Having of next momentum head balance inception, evidence XXXX. improving and order communicating continues forward and quarter. in specifics well elements our and RPT future.
We In we by cornerstone sheet as an our conducted demonstrated we This refreshed assessing and and encouraged important since a to be care the management a care efficiency strategy support work over this the for investments. patient and results are ever and early supporting generating the support is in progressing launching among on remains is largest readout also and neck and
I Before capital share call to to our a on Elaine, turning brief want allocation strategy. update over the
ability free earnings our As evaluate communicated investment in trend call continue. as clear, we meaningful increase repurchase during of of of strong incremental our outlook have balance our and also of quarter outstanding now us leadership operational capital $XX Elaine luxury sheet mentioned flow, believe the execute the our and prepared well growth.
With up to evaluate in and opportunities continuing to my that, a the drive of various shareholder an action market terms provides to invest trajectory initiatives.
To are previous remarks, remainder financial generating in will to to ways initiating update a to on This aligns us leverage and our to review increasingly strategic the our and use and be business of earlier in as our drive stock.
We a and with we of strong results options third our multitude financial from and value we benefiting for conviction growth cash XXXX. operational expect provide million the I'll deployment, commercial and while affords to cash continue near-term of program share footprint
